Selected references
- Epstein AE, Bigger JT Jr, Wyse DG, Romhilt DW, Reynolds-Haertle RA,
Hallstrom AP. Events in the Cardiac Arrhythmia Suppression Trial (CAST):
mortality in the entire population enrolled. J Am Coll Cardiol
1991 Jul;18(1):14-19. Erratum in: J Am Coll Cardiol
1991 Sep;18(3):888.
[Abstract]
- Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH,
Arensberg D, Baker A, Friedman L, Greene HL, Richardson DW, and the CAST
Investigators. Mortality and morbidity in patients receiving encainide,
flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J
Med 1991 Mar 21;324(12):781-8. Comment in N Engl J Med 1991
Aug 22;325(8):584-5. Comment in N Engl J Med 1992 Dec
17;327(25):1818.
[Abstract]
- The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the
antiarrhythmic agent moricizine on survival after myocardial infraction. N
Engl J Med 1992 Jul;327:227-33.
[Abstract]
- Hallstrom A, Pratt CM, Greene HL, Huther M, Gottlieb S, DeMaria A, Young
JB. Relations between heart failure, ejection fraction, arrhythmia suppression
and mortality: analysis of the Cardiac Arrhythmia Suppression Trial. J Am
Coll Cardiol 1995 May;25(6):1250-7.
[Abstract]
- Stein PK, Domitrovich PP, Kleiger RE, Schechtman KB, Rottman JN. Clinical
and demographic determinants of heart rate variability in patients post
myocardial infarction: insights from the Cardiac Arrhythmia Suppression Trial
(CAST). Clin Cardiol 2000 Mar;23(3):187-94.
[Abstract]
-
Stein PK, Domitrovich PP, Kleiger RE; CAST Investigators. Including patients
with diabetes mellitus or coronary artery bypass grafting decreases the
association between heart rate variability and mortality after myocardial
infarction. Am Heart J 2004 Feb;147(2):309-16.
[Abstract]
Many additional publications that discuss the CAST and CAST II studies are
listed here.
CRISDB home
